CN111246880A - 用于治疗炎性胃肠道障碍的方法和组合物 - Google Patents

用于治疗炎性胃肠道障碍的方法和组合物 Download PDF

Info

Publication number
CN111246880A
CN111246880A CN201880044727.6A CN201880044727A CN111246880A CN 111246880 A CN111246880 A CN 111246880A CN 201880044727 A CN201880044727 A CN 201880044727A CN 111246880 A CN111246880 A CN 111246880A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antibody
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880044727.6A
Other languages
English (en)
Chinese (zh)
Inventor
C·R·贝宾顿
B·A·扬布拉德
N·托马舍维奇
E·C·布鲁克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philharmonic
Original Assignee
Philharmonic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philharmonic filed Critical Philharmonic
Publication of CN111246880A publication Critical patent/CN111246880A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A61K39/225—Porcine transmissible gastroenteritis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Multimedia (AREA)
  • Theoretical Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880044727.6A 2017-05-05 2018-05-04 用于治疗炎性胃肠道障碍的方法和组合物 Pending CN111246880A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762502480P 2017-05-05 2017-05-05
US62/502,480 2017-05-05
US201762572337P 2017-10-13 2017-10-13
US62/572,337 2017-10-13
PCT/US2018/031231 WO2018204871A1 (en) 2017-05-05 2018-05-04 Methods and compositions for treating inflammatory gastrointestinal disorders

Publications (1)

Publication Number Publication Date
CN111246880A true CN111246880A (zh) 2020-06-05

Family

ID=64016746

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880044727.6A Pending CN111246880A (zh) 2017-05-05 2018-05-04 用于治疗炎性胃肠道障碍的方法和组合物

Country Status (13)

Country Link
US (1) US20200270344A1 (enExample)
EP (1) EP3618872A4 (enExample)
JP (2) JP7346304B2 (enExample)
KR (1) KR20200015511A (enExample)
CN (1) CN111246880A (enExample)
AU (1) AU2018263937A1 (enExample)
BR (1) BR112019022957A2 (enExample)
CA (1) CA3062430A1 (enExample)
IL (1) IL270304B2 (enExample)
MX (1) MX2019013136A (enExample)
SG (2) SG10202112259VA (enExample)
WO (1) WO2018204871A1 (enExample)
ZA (1) ZA201907372B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116615182A (zh) * 2020-10-22 2023-08-18 爱乐科斯公司 抗siglec-8抗体制剂

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
HK1254432A1 (zh) 2015-06-17 2019-07-19 Allakos Inc. 用於治疗纤维性疾病的方法和组合物
BR112019022912A2 (pt) 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
CA3087063A1 (en) 2017-12-29 2019-07-04 Cornell University Gene therapy for eosinophilic disorders
BR112021015009A2 (pt) * 2019-02-15 2021-10-05 Allakos Inc. Métodos e composições para o tratamento da gastrite mastocística, esofagite mastocística, enterite mastocística, duodenite mastocística e/ou gastroenterite mastocística
MX2022001403A (es) * 2019-08-02 2022-03-25 Allakos Inc Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
WO2021081411A1 (en) * 2019-10-24 2021-04-29 Allakos Inc. Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
EP4469601A1 (en) * 2022-01-24 2024-12-04 Children's Hospital Medical Center Methods of treating eosinophilic colitis
US20240225536A9 (en) * 2022-10-21 2024-07-11 Case Western Reserve University Radiomics signatures for pathologic characterization of strictures on mr and ct enterography
IL323497A (en) * 2023-03-27 2025-11-01 Regeneron Pharma Methods for treating eosinophilic gastroenteritis by administering an IL-4R antagonist
CN117187180B (zh) * 2023-11-03 2024-01-26 四川大学 一种Th17细胞及其培养方法和应用及其诱导液

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150203578A1 (en) * 2013-12-09 2015-07-23 Allakos Inc. Anti-siglec-8 antibodies and methods of use thereof
CN105392497A (zh) * 2013-07-11 2016-03-09 瑞泽恩制药公司 以il-4r抑制剂治疗嗜酸性食管炎的方法
US20170073413A1 (en) * 2014-02-28 2017-03-16 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745421B2 (en) * 2004-05-25 2010-06-29 The Johns Hopkins University Methods and compositions for treating diseases and disorders associated with Siglec-8 expressing cells
AU2008255352B2 (en) * 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
CA2745439C (en) * 2008-12-03 2019-10-15 Genmab A/S Antibody variants having modifications in the constant region
EP2465873A1 (en) * 2010-12-16 2012-06-20 Deutsches Rheuma-Forschungszentrum Berlin Eosinophils as a therapeutic target
AU2012272559C1 (en) * 2011-06-23 2017-04-20 Children's Hospital Medical Center Molecular diagnostic panel of eosinophilic gastrointestinal disorders
US9260756B2 (en) * 2012-02-24 2016-02-16 Children's Hospital Medical Center Esophageal microRNA expression profiles in eosinophilic esophagitis
HK1254432A1 (zh) * 2015-06-17 2019-07-19 Allakos Inc. 用於治疗纤维性疾病的方法和组合物
US10604577B2 (en) * 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
BR112019022912A2 (pt) * 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
GB201820174D0 (en) * 2018-12-11 2019-01-23 Nordic Semiconductor Asa Radio communication
BR112021015009A2 (pt) * 2019-02-15 2021-10-05 Allakos Inc. Métodos e composições para o tratamento da gastrite mastocística, esofagite mastocística, enterite mastocística, duodenite mastocística e/ou gastroenterite mastocística
JP2022535400A (ja) * 2019-06-07 2022-08-08 エピセリオン サイエンス バイオテック，エセ．エレ． 好酸球性消化管疾患の処置のためのイルソグラジン
MX2022001403A (es) * 2019-08-02 2022-03-25 Allakos Inc Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
WO2021081411A1 (en) * 2019-10-24 2021-04-29 Allakos Inc. Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
JP2023511279A (ja) * 2020-01-13 2023-03-17 フルーエント バイオサイエンシーズ インコーポレイテッド 単一細胞シーケンシング
AU2021365008A1 (en) * 2020-10-22 2023-06-08 Allakos Inc. Anti-siglec-8 antibody formulations
US20240254441A1 (en) * 2021-06-04 2024-08-01 Kirin Holdings Kabushiki Kaisha Cell composition, method for producing cell composition, and pharmaceutical composition containing cell composition
KR20250007535A (ko) * 2022-04-22 2025-01-14 인히브릭스 바이오사이언스, 인크. Siglec-8 결합 단백질 및 그 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105392497A (zh) * 2013-07-11 2016-03-09 瑞泽恩制药公司 以il-4r抑制剂治疗嗜酸性食管炎的方法
US20150203578A1 (en) * 2013-12-09 2015-07-23 Allakos Inc. Anti-siglec-8 antibodies and methods of use thereof
CN105916519A (zh) * 2013-12-09 2016-08-31 阿拉科斯公司 抗Siglec-8抗体及其使用方法
US20170073413A1 (en) * 2014-02-28 2017-03-16 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKUMI KIWAMOTO 等: "Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116615182A (zh) * 2020-10-22 2023-08-18 爱乐科斯公司 抗siglec-8抗体制剂

Also Published As

Publication number Publication date
IL270304B1 (en) 2024-03-01
AU2018263937A1 (en) 2019-12-05
IL270304A (en) 2019-12-31
JP7346304B2 (ja) 2023-09-19
IL270304B2 (en) 2024-07-01
US20200270344A1 (en) 2020-08-27
CA3062430A1 (en) 2018-11-08
KR20200015511A (ko) 2020-02-12
SG10202112259VA (en) 2021-12-30
ZA201907372B (en) 2024-04-24
SG11201910206QA (en) 2019-11-28
JP2020518645A (ja) 2020-06-25
EP3618872A1 (en) 2020-03-11
BR112019022957A2 (pt) 2020-05-19
MX2019013136A (es) 2020-07-14
WO2018204871A1 (en) 2018-11-08
EP3618872A4 (en) 2021-06-30
JP2023099232A (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
JP7346304B2 (ja) 炎症性消化器障害を処置するための方法および組成物
JP6549143B2 (ja) 抗シグレック−８抗体およびその使用の方法
JP2017501744A5 (enExample)
JP7034911B2 (ja) 全身性肥満細胞症を処置するための方法および組成物
US20220135673A1 (en) Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
JP2023086917A (ja) アレルギー性眼疾患を処置するための方法および組成物
JP2024534429A (ja) 抗ｓｉｇｌｅｃ－６抗体およびその使用方法
US20220257758A1 (en) Methods of administering anti-siglec-8 antibodies and corticosteroids
JP2024045612A (ja) 慢性蕁麻疹を処置するための方法および組成物
US20190338027A1 (en) Methods and compositions for treating chronic obstructive pulmonary disorder
WO2022061032A1 (en) Methods and compositions for treating viral infection
JP2022553378A (ja) 過敏性腸症候群および機能性ディスペプシアを処置するための方法および組成物
EA046789B1 (ru) Способы и композиции для лечения воспалительных расстройств желудочно-кишечного тракта
WO2024006820A1 (en) Anti-siglec-10 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination